Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet

Table 1 Original Measles Vaccination Balance Sheet.

(1) Condition	(2) Measles complication rate among unvaccinated^a	(3) Vaccine adverse event rate	(4) Risk Difference	(5) Number Needed to Treat (NNT)	(6) Expected Gain per thousand^e
Diarrhoea in highly developed countries	0.08	0.0357	0.0443	23	30
Diarrhoea - WHO South Asia subregion adjusted	0.41	0.0045	0.4055	3	277
Bronchopneumonia in highly developed countries	0.01-0.06	0	0.01	100	7
Bronchopneumonia - WHO South Asia subregion adjusted	0.089-0.53	0	0.089	11	61
Blindness (Africa)	0.04 ^b	0	0.04	25	27
Otitis media	0.07-0.09	0.0333	0.0367	27	25
Death in highly developed countries	0.001-0.003	0.0002	0.0008	1,189	0.6
Death - WHO South Asia subregion data	0.0228	0.0002	0.0208	50	14
Death in developing world (by some estimates)	15%	0.0002	0.1498	7	102
Convulsions	0.006-0.007^c	0.0022	0.0038	266	3
Post-infectious encephalitis	0.001-0.0005	0.0004	0.0006	1,591	0.4
Subacute sclerosing panencephalitis (SSPE)	0.00001	0	0.00001	100,000	7/million
Anaphylaxis	0^d	1-3.5 per million	-0.000001	-1,000,000	-7/ten million

^a Except where noted all figures in this column taken from Strebel et al [44]. ^b [45]. ^c [51]. ^d [33].
^e Gain = RDx(PRIxVER), where RD = risk difference, PRI = proportion requiring intervention (0.76), VER = vaccine efficacy rate (0.90).
The bold-font rows show the conditions for which the data are most applicable to the South Asia region or, at least, developing country conditions - diarrhoea, pneumonia, blindness and death.

ISSN: 1472-698X